21 CFR 520.623
§ 520.623 Diethylcarbamazine and oxibendazole chewable tablets.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 520.623, § 520.623 Diethylcarbamazine and oxibendazole chewable tablets, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87136
- Permanent ID
ys:prov:87136@1- SHA-256
d3688152e77804bf3334c49c703e26bc149413e4297266aae9d358137efc9c75
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Specifications. Each tablet contains either 60, 120, or 180 milligrams of diethylcarbamazine citrate with 45, 91, or 136 milligrams of oxibendazole, respectively.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Amount. Administer orally to dogs at a dosage level of 6.6 milligrams of diethylcarbamazine citrate per kilogram of body weight (3 milligrams per pound of body weight) and 5.0 milligrams of oxibendazole per kilogram of body weight (2.27 milligrams per pound of body weight).
(2) Indications for use. For prevention of infection with Dirofilaria immitis (heartworm disease) and Ancylostoma caninum (hookworm infection) and for removal and control of Trichuris vulpis (whipworm infection) and mature and immature stages of intestinal Toxocara canis (ascarid infection).
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.